Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Prospective, Phase 2a Study to Evaluate the Effectiveness and Safety of DPCP Ointment (Samcyprone™) on the Clearance of Verruca Vulgaris (Common Warts) in Subjects Ages 18 - 65 Years

NCT02640820 is registered in ClinicalTrials.gov with RXi Pharmaceuticals, Corp. as lead sponsor.

NCT NCT02640820
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02640820 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Prospective, Phase 2a Study to Evaluate the Effectiveness and Safety of DPCP Ointment (Samcyprone™) on the Clearance of Verruca Vulgaris (Common Warts) in Subjects Ages 18 - 65 Years
Lead sponsor
RXi Pharmaceuticals, Corp.
Phase
Phase 2
Overall status
Unknown status
Start date
December 31, 2015
Completion date
May 31, 2018
Enrollment
83 (actual)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

common warts, hpv (human papillomavirus), periungual warts, plantar warts